New phase-III data support Roche’s Tecentriq in early-stage lung cancer
As published in The Lancet, Tecentriq is the first and only cancer immunotherapy to demonstrate positive phase-III results in the…
Recover your password.
A password will be e-mailed to you.
Recover your password.
A password will be e-mailed to you.